191 related articles for article (PubMed ID: 37111254)
1. Clearing and Masking Agents in Pretargeting Strategies.
Staudt M; Herth MM
Pharmaceuticals (Basel); 2023 Mar; 16(4):. PubMed ID: 37111254
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging.
García-Vázquez R; Battisti UM; Herth MM
Pharmaceuticals (Basel); 2022 May; 15(6):. PubMed ID: 35745604
[TBL] [Abstract][Full Text] [Related]
3. Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines.
Stéen EJL; Edem PE; Nørregaard K; Jørgensen JT; Shalgunov V; Kjaer A; Herth MM
Biomaterials; 2018 Oct; 179():209-245. PubMed ID: 30007471
[TBL] [Abstract][Full Text] [Related]
4. Diels-Alder reaction for tumor pretargeting: in vivo chemistry can boost tumor radiation dose compared with directly labeled antibody.
Rossin R; Läppchen T; van den Bosch SM; Laforest R; Robillard MS
J Nucl Med; 2013 Nov; 54(11):1989-95. PubMed ID: 24092936
[TBL] [Abstract][Full Text] [Related]
5. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction.
Rossin R; van Duijnhoven SM; Läppchen T; van den Bosch SM; Robillard MS
Mol Pharm; 2014 Sep; 11(9):3090-6. PubMed ID: 25077373
[TBL] [Abstract][Full Text] [Related]
6. Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers.
Meyer JP; Tully KM; Jackson J; Dilling TR; Reiner T; Lewis JS
Bioconjug Chem; 2018 Feb; 29(2):538-545. PubMed ID: 29378403
[TBL] [Abstract][Full Text] [Related]
7. Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo.
Poulie CBM; Sporer E; Hvass L; Jørgensen JT; Kempen PJ; Lopes van den Broek SI; Shalgunov V; Kjaer A; Jensen AI; Herth MM
Chemistry; 2022 Nov; 28(61):e202201847. PubMed ID: 35851967
[TBL] [Abstract][Full Text] [Related]
8. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
9. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry.
van de Watering FC; Rijpkema M; Robillard M; Oyen WJ; Boerman OC
Front Med (Lausanne); 2014; 1():44. PubMed ID: 25593917
[TBL] [Abstract][Full Text] [Related]
10. Development of
García-Vázquez R; Jørgensen JT; Bratteby KE; Shalgunov V; Hvass L; Herth MM; Kjær A; Battisti UM
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215356
[TBL] [Abstract][Full Text] [Related]
11. Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy.
Membreno R; Keinänen OM; Cook BE; Tully KM; Fung KC; Lewis JS; Zeglis BM
Mol Pharm; 2019 May; 16(5):2259-2263. PubMed ID: 30912951
[TBL] [Abstract][Full Text] [Related]
12. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer.
Hapuarachchige S; Huang CT; Donnelly MC; Bařinka C; Lupold SE; Pomper MG; Artemov D
Mol Pharm; 2020 Jan; 17(1):98-108. PubMed ID: 31840521
[TBL] [Abstract][Full Text] [Related]
13. Pretargeted Imaging beyond the Blood-Brain Barrier-Utopia or Feasible?
Lopes van den Broek S; Shalgunov V; García Vázquez R; Beschorner N; Bidesi NSR; Nedergaard M; Knudsen GM; Sehlin D; Syvänen S; Herth MM
Pharmaceuticals (Basel); 2022 Sep; 15(10):. PubMed ID: 36297303
[TBL] [Abstract][Full Text] [Related]
14. Diabody Pretargeting with Click Chemistry In Vivo.
van Duijnhoven SM; Rossin R; van den Bosch SM; Wheatcroft MP; Hudson PJ; Robillard MS
J Nucl Med; 2015 Sep; 56(9):1422-8. PubMed ID: 26159589
[TBL] [Abstract][Full Text] [Related]
15. Development of the First Aliphatic
Battisti UM; Bratteby K; Jørgensen JT; Hvass L; Shalgunov V; Mikula H; Kjær A; Herth MM
J Med Chem; 2021 Oct; 64(20):15297-15312. PubMed ID: 34649424
[TBL] [Abstract][Full Text] [Related]
16. Pretargeting of internalizing trastuzumab and cetuximab with a
Keinänen O; Fung K; Pourat J; Jallinoja V; Vivier D; Pillarsetty NK; Airaksinen AJ; Lewis JS; Zeglis BM; Sarparanta M
EJNMMI Res; 2017 Dec; 7(1):95. PubMed ID: 29198065
[TBL] [Abstract][Full Text] [Related]
17. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.
Altai M; Perols A; Tsourma M; Mitran B; Honarvar H; Robillard M; Rossin R; ten Hoeve W; Lubberink M; Orlova A; Karlström AE; Tolmachev V
J Nucl Med; 2016 Mar; 57(3):431-6. PubMed ID: 26659353
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the inverse electron demand Diels-Alder reaction in rats using a scandium-44-labelled tetrazine for pretargeted PET imaging.
Edem PE; Sinnes JP; Pektor S; Bausbacher N; Rossin R; Yazdani A; Miederer M; Kjær A; Valliant JF; Robillard MS; Rösch F; Herth MM
EJNMMI Res; 2019 May; 9(1):49. PubMed ID: 31140047
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Targeting Nuclear Molecular Imaging Driven by Tetrazine Bioorthogonal Chemistry.
Dong P; Wang X; Zheng J; Zhang X; Li Y; Wu H; Li L
Curr Med Chem; 2020; 27(23):3924-3943. PubMed ID: 31267851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
